Holen Sie sich die Stockscreener-App
60.99
2.21%
1.32
Handel nachbörslich:
60.99
Schlusskurs vom Vortag:
$59.67
Offen:
$61.08
24-Stunden-Volumen:
1.00M
Relative Volume:
0.91
Marktkapitalisierung:
$5.09B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
7.8835
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
-2.51%
1M Leistung:
-7.10%
6M Leistung:
-17.10%
1J Leistung:
-10.98%
1-Tages-Spanne:
$59.88
$62.31
1-Wochen-Bereich:
$58.80
$65.03
52-Wochen-Spanne:
$58.80
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
60.99 | 5.09B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2026-06-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2026-05-27 | Hochstufung | Jefferies | Hold → Buy |
| 2026-05-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Form 4 PTC Therapeutics Inc: Mark Elliott Boulding (EXEC. VP AND CLO) For: 9 October - Investing.com Canada
PTC Therapeutics CLO Mark Boulding sells $12,337 in stock - Investing.com
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock - MarketBeat
After exercising options at $39.42, PTC Therapeutics (PTCT) CLO Boulding sells 192 shares. - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month LowTime to Sell? - MarketBeat
Ptc Therapeutics stock hits 52-week low at $61.20 - Investing.com
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Form 4 PTC Therapeutics Inc: Glenn JR MD Phd Steele (Director) For: 30 September - Investing.com Nigeria
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Gets Downgrade from Wall Street Zen - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock - MarketBeat
Under a trading plan, Section Six sells 2,500 PTC Therapeutics (PTCT) shares. - Stock Titan
Officer Mark Elliott Boulding proposes selling 192 shares of PTC Therapeutics (Nasdaq: PTCT). - Stock Titan
PTC Therapeutics insider sold 1,638 shares while PTC Therapeutics stock fell 1.36 percent - AD HOC NEWS
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo! Finance Canada
RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating - www.marketscreener.com
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Shares - MarketBeat
Form 4 PTC Therapeutics Inc For: 7 October By Investing.com - Investing.com India
PTC Therapeutics CLO Mark Boulding sells $132,790 in shares - Investing.com
Form 4 PTC Therapeutics Inc For: 7 October By Investing.com - Investing.com UK
Under a trading plan, PTC Therapeutics (PTCT) CLO sells 1,638 shares, then 435 more. - Stock Titan
Director-linked partnership proposes selling 10,000 PTC Therapeutics (PTCT) shares. - Stock Titan
PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says - marketscreener.com
RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform By Investing.com - Investing.com Canada
Form 144 PTC THERAPEUTICS For: 6 October By Investing.com - Investing.com Nigeria
Cantor raises target for PTC Therapeutics stock to USD 137.00 - AD HOC NEWS
A $27.9K sale of 435 shares is proposed by PTC Therapeutics (PTCT) officer Mark Boulding. - Stock Titan
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Officer Mark Boulding proposes selling 1,638 shares of PTC Therapeutics (PTCT). - stocktitan.net
PTC Therapeutics, Inc. (PTCT) Stock forecasts - uk.finance.yahoo.com
Director Steele Glenn Jr MD PHD Sells 12,000 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock - MarketBeat
After exercising options at $11.23, a director sold 12,000 PTC Therapeutics (PTCT) shares at $65.16. - stocktitan.net
PTCT Stock Price, Quote & Chart - ChartMill
A director proposes selling $782K in option-exercised PTC Therapeutics (PTCT) shares. - Stock Titan
Non-controlling/minority interest of PTC Therapeutics, Inc. – HAN:BH3 - TradingView
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo! Finance Canada
PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7%Here's What Happened - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
37 new hires get options to buy PTC shares at $65.96 - Stock Titan
Cantor raises PTC Therapeutics stock price target on Fabry deal By Investing.com - Investing.com Canada
Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00 - MarketBeat
Cantor Fitzgerald maintains Overweight rating on PTC Therapeutics, $137 price target - TradingView
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com - Investing.com Australia
PTC Completes Acquisition of ST-920, BLA Submission Expected in Q4 2026 - TradingView
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy - marketscreener.com
A one-time gene therapy for Fabry disease is now PTC’s. FDA filing expected later in 2026. - Stock Titan
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 09 '26 |
Sale |
64.26 |
192 |
12,338 |
105,272 |
| Boulding Mark Elliott | Officer |
Oct 09 '26 |
Proposed Sale |
64.26 |
192 |
12,339 |
0 |
| Section Six Partners, L.P. | Affiliate of Director |
Oct 07 '26 |
Proposed Sale |
64.35 |
10,000 |
643,500 |
0 |
| SCHMERTZLER MICHAEL | Director |
Oct 07 '26 |
Sale |
63.39 |
2,500 |
158,480 |
1,294,094 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 06 '26 |
Sale |
64.16 |
435 |
27,910 |
105,272 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 06 '26 |
Option Exercise |
39.42 |
435 |
17,148 |
105,707 |
| Boulding Mark Elliott | Officer |
Oct 06 '26 |
Proposed Sale |
64.16 |
435 |
27,908 |
0 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 05 '26 |
Option Exercise |
39.42 |
1,638 |
64,570 |
106,910 |
| Boulding Mark Elliott | Officer |
Oct 05 '26 |
Proposed Sale |
64.03 |
1,638 |
104,883 |
0 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 05 '26 |
Sale |
64.03 |
1,638 |
104,881 |
105,272 |
4.83%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):